Palantir Technologies Inc. stock is in a technical bear market, down 20% from its all-time high. Explore more details here.

Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by ...

The major market averages were higher on Friday, a day after Wall Street kicked off 2025 with a choppy first trading session.

Value stocks come into 2025 with some momentum. While the annual returns versus growth stocks paled in comparison, value stocks closed the gap somewhat in the second half. Over the past six months, ...